Reyes Financial Architecture Inc. Acquires 321 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Reyes Financial Architecture Inc. raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 22.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,721 shares of the biopharmaceutical company’s stock after buying an additional 321 shares during the quarter. Reyes Financial Architecture Inc.’s holdings in Halozyme Therapeutics were worth $110,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Bessemer Group Inc. grew its position in Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 207 shares during the last quarter. CBIZ Investment Advisory Services LLC bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $29,000. Heck Capital Advisors LLC acquired a new stake in Halozyme Therapeutics during the fourth quarter worth about $29,000. Park Place Capital Corp increased its stake in Halozyme Therapeutics by 20.1% during the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after acquiring an additional 182 shares during the period. Finally, UMB Bank n.a. raised its holdings in Halozyme Therapeutics by 267.4% in the 1st quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company’s stock valued at $84,000 after acquiring an additional 960 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on HALO shares. HC Wainwright reissued a “buy” rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, May 29th. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 13th. Benchmark cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. The Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a research report on Thursday. They set a “neutral” rating and a $55.00 target price on the stock. Finally, JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a research note on Monday, April 21st. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Hold” and a consensus price target of $62.50.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total value of $1,128,600.00. Following the completion of the sale, the chief executive officer owned 733,719 shares of the company’s stock, valued at $41,403,763.17. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jeffrey William Henderson sold 4,497 shares of the company’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $60.37, for a total value of $271,483.89. Following the transaction, the director directly owned 28,611 shares in the company, valued at approximately $1,727,246.07. This represents a 13.58% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 64,497 shares of company stock worth $3,533,884. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Trading Down 0.8%

Shares of Halozyme Therapeutics stock opened at $57.15 on Friday. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $70.51. The stock has a market capitalization of $7.04 billion, a P/E ratio of 15.20, a price-to-earnings-growth ratio of 0.38 and a beta of 1.15. The company has a 50-day simple moving average of $55.03 and a 200 day simple moving average of $56.95. The company has a quick ratio of 7.30, a current ratio of 8.39 and a debt-to-equity ratio of 3.13.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.13. The company had revenue of $264.86 million during the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The company’s revenue was up 35.2% on a year-over-year basis. During the same quarter last year, the business posted $0.79 earnings per share. Research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.